Related references
Note: Only part of the references are listed.Nucleofection with Plasmid DNA for CRISPR/Cas9-Mediated Inactivation of Programmed Cell Death Protein 1 in CD133-Specific CAR T Cells
Bian Hu et al.
HUMAN GENE THERAPY (2019)
Activity of Mesothelin-Specific Chimeric Antigen Receptor T Cells Against Pancreatic Carcinoma Metastases in a Phase 1 Trial
Gregory L. Beatty et al.
GASTROENTEROLOGY (2018)
Immune checkpoint blockade therapy for cancer: An overview of FDA-approved immune checkpoint inhibitors
Kristian M. Hargadon et al.
INTERNATIONAL IMMUNOPHARMACOLOGY (2018)
Chimeric Antigen Receptor T Cell Therapy: Challenges to Bench-to-Bedside Efficacy
Shivani Srivastava et al.
JOURNAL OF IMMUNOLOGY (2018)
An off-the-shelf fratricide-resistant CAR-T for the treatment of T cell hematologic malignancies
Matthew L. Cooper et al.
LEUKEMIA (2018)
Determinants of response and resistance to CD19 chimeric antigen receptor (CAR) T cell therapy of chronic lymphocytic leukemia
Joseph A. Fraietta et al.
NATURE MEDICINE (2018)
CAR T cell-induced cytokine release syndrome is mediated by macrophages and abated by IL-1 blockade
Theodoros Giavridis et al.
NATURE MEDICINE (2018)
Inhibition of Interleukin-10 in the tumor microenvironment can restore mesothelin chimeric antigen receptor T cell activity in pancreatic cancer in vitro
Ramesh B. Batchu et al.
SURGERY (2018)
Enhancing the Potency and Specificity of Engineered T Cells for Cancer Treatment
Sujita Sukumaran et al.
CANCER DISCOVERY (2018)
Emerging strategies for combination checkpoint modulators in cancer immunotherapy
Aleksandra Popovic et al.
JOURNAL OF CLINICAL INVESTIGATION (2018)
CAR T Cells in Solid Tumors: Blueprints for Building effective Therapies
Hannah M. Knochelmann et al.
FRONTIERS IN IMMUNOLOGY (2018)
Pancreatic cancer therapy with combined mesothelin-redirected chimeric antigen receptor T cells and cytokine-armed oncolytic adenoviruses
Keisuke Watanabe et al.
JCI INSIGHT (2018)
Improving T-cell expansion and function for adoptive T-cell therapy using ex vivo treatment with PI3Kδ inhibitors and VIP antagonists
Christopher T. Petersen et al.
BLOOD ADVANCES (2018)
Enhancing CAR T cell persistence through ICOS and 4-1BB costimulation
Sonia Guedan et al.
JCI INSIGHT (2018)
Multiplex Genome Editing to Generate Universal CAR T Cells Resistant to PD1 Inhibition
Jiangtao Ren et al.
CLINICAL CANCER RESEARCH (2017)
Biopolymers codelivering engineered T cells and STING agonists can eliminate heterogeneous tumors
Tyrel T. Smith et al.
JOURNAL OF CLINICAL INVESTIGATION (2017)
Lymphoma Remissions Caused by Anti-CD19 Chimeric Antigen Receptor T Cells Are Associated With High Serum Interleukin-15 Levels
James N. Kochenderfer et al.
JOURNAL OF CLINICAL ONCOLOGY (2017)
Phase 1 Results of ZUMA-1: A Multicenter Study of KTE-C19 Anti-CD19 CAR T Cell Therapy in Refractory Aggressive Lymphoma
Frederick L. Locke et al.
MOLECULAR THERAPY (2017)
Therapeutic T cell engineering
Michel Sadelain et al.
NATURE (2017)
A Milestone for CAR T Cells
Eric Tran et al.
NEW ENGLAND JOURNAL OF MEDICINE (2017)
Chimeric Antigen Receptor T Cells in Refractory B-Cell Lymphomas
Stephen J. Schuster et al.
NEW ENGLAND JOURNAL OF MEDICINE (2017)
Axicabtagene Ciloleucel CAR T-Cell Therapy in Refractory Large B-Cell Lymphoma
S. S. Neelapu et al.
NEW ENGLAND JOURNAL OF MEDICINE (2017)
Human CD26high T cells elicit tumor immunity against multiple malignancies via enhanced migration and persistence
Stefanie R. Bailey et al.
NATURE COMMUNICATIONS (2017)
Genome-Editing Technologies in Adoptive T Cell Immunotherapy for Cancer
Nathan Singh et al.
CURRENT HEMATOLOGIC MALIGNANCY REPORTS (2017)
Efficient growth suppression in pancreatic cancer PDX model by fully human anti-mesothelin CAR-T cells
Hua Jiang et al.
PROTEIN & CELL (2017)
Chimeric antigen receptor (CAR) T and other T cell strategies for pancreas adenocarcinoma
Anna M. Varghese
CHINESE CLINICAL ONCOLOGY (2017)
Cancer Statistics, 2017
Rebecca L. Siegel et al.
CA-A CANCER JOURNAL FOR CLINICIANS (2017)
Enhanced Cancer Immunotherapy by Chimeric Antigen Receptor-Modified T Cells Engineered to Secrete Checkpoint Inhibitors
Si Li et al.
CLINICAL CANCER RESEARCH (2017)
The clinical efficacy of first-generation carcinoembryonic antigen (CEACAM5)-specific CAR T cells is limited by poor persistence and transient pre-conditioning-dependent respiratory toxicity
Fiona C. Thistlethwaite et al.
CANCER IMMUNOLOGY IMMUNOTHERAPY (2017)
Outcomes in refractory diffuse large B-cell lymphoma: results from the international SCHOLAR-1 study
Michael Crump et al.
BLOOD (2017)
Mesothelin-Targeted CARs: Driving T Cells to Solid Tumors
Aurore Morello et al.
CANCER DISCOVERY (2016)
ZUMA-2: A phase 2 multi-center study evaluating the efficacy of KTE-C19 (Anti-CD19 CAR T cells) in patients with relapsed/refractory Mantle cell lymphoma (R/R MCL)
M. Wang et al.
ANNALS OF ONCOLOGY (2016)
ZUMA-3: A phase 1/2 multi-center study evaluation the safety and efficacy of KTE-C19 anti-CD19 CAR T cells in adult patients with relapsed/refractory B precursor acute lymphoblastic leukemia (R/R ALL)
B. Shah et al.
ANNALS OF ONCOLOGY (2016)
Engineered CAR T Cells Targeting the Cancer-Associated Tn-Glycoform of the Membrane Mucin MUC1 Control Adenocarcinoma
Avery D. Posey et al.
IMMUNITY (2016)
Mesothelin as a target for chimeric antigen receptor-modified T cells as anticancer therapy
Mark O'Hara et al.
IMMUNOTHERAPY (2016)
Human CAR T cells with cell-intrinsic PD-1 checkpoint blockade resist tumor-mediated inhibition
Leonid Cherkassky et al.
JOURNAL OF CLINICAL INVESTIGATION (2016)
Translational Implications for Off-the-shelf Immune Cells Expressing Chimeric Antigen Receptors
Hiroki Torikai et al.
MOLECULAR THERAPY (2016)
Defining CD8+ T cells that provide the proliferative burst after PD-1 therapy
Se Jin Im et al.
NATURE (2016)
Hurdles of CAR-T cell-based cancer immunotherapy directed against solid tumors
Bing-Lan Zhang et al.
SCIENCE CHINA-LIFE SCIENCES (2016)
Chimeric antigen receptor T cells secreting anti-PD-L1 antibodies more effectively regress renal cell carcinoma in a humanized mouse model
Eloah Rabello Suarez et al.
ONCOTARGET (2016)
ZUMA-4: A phase 1/2 multicenter study evaluating the safety and efficacy of KTE-C19 (anti-CD19 CAR T cells) in pediatric and adolescent subjects with relapsed/refractory B-precursor acute lymphoblastic leukemia (r/r ALL).
Alan S. Wayne et al.
JOURNAL OF CLINICAL ONCOLOGY (2016)
Chemotherapy-Refractory Diffuse Large B-Cell Lymphoma and Indolent B-Cell Malignancies Can Be Effectively Treated With Autologous T Cells Expressing an Anti-CD19 Chimeric Antigen Receptor
James N. Kochenderfer et al.
JOURNAL OF CLINICAL ONCOLOGY (2015)
Heparanase promotes tumor infiltration and antitumor activity of CAR-redirected T lymphocytes
Ignazio Caruana et al.
NATURE MEDICINE (2015)
Identification of Chimeric Antigen Receptors That Mediate Constitutive or Inducible Proliferation of T Cells
Matthew J. Frigault et al.
CANCER IMMUNOLOGY RESEARCH (2015)
ICOS-based chimeric antigen receptors program bipolar TH17/TH1 cells
Sonia Guedan et al.
BLOOD (2014)
Discovery of Mesothelin and Exploiting It as a Target for Immunotherapy
Ira Pastan et al.
CANCER RESEARCH (2014)
Projecting Cancer Incidence and Deaths to 2030: The Unexpected Burden of Thyroid, Liver, and Pancreas Cancers in the United States
Lola Rahib et al.
CANCER RESEARCH (2014)
Multifactorial T-cell Hypofunction That Is Reversible Can Limit the Efficacy of Chimeric Antigen Receptor-Transduced Human T cells in Solid Tumors
Edmund K. Moon et al.
CLINICAL CANCER RESEARCH (2014)
A Novel Chimeric Antigen Receptor Against Prostate Stem Cell Antigen Mediates Tumor Destruction in a Humanized Mouse Model of Pancreatic Cancer
Daniel Abate-Daga et al.
HUMAN GENE THERAPY (2014)
Chimeric Antigen Receptor T Cells for Sustained Remissions in Leukemia
Shannon L. Maude et al.
NEW ENGLAND JOURNAL OF MEDICINE (2014)
Expansion of Anti-Mesothelin Specific CD4+ and CD8+ T Cell Responses in Patients with Pancreatic Carcinoma
Yuan Chen et al.
PLOS ONE (2014)
Regional delivery of mesothelin-targeted CAR T cell therapy generates potent and long-lasting CD4-dependent tumor immunity
Prasad S. Adusumilli et al.
SCIENCE TRANSLATIONAL MEDICINE (2014)
Mesothelin-Specific Chimeric Antigen Receptor mRNA-Engineered T Cells Induce Antitumor Activity in Solid Malignancies
Gregory L. Beatty et al.
CANCER IMMUNOLOGY RESEARCH (2014)
Engineered chimeric antigen receptor-expressing T cells for the treatment of pancreatic ductal adenocarcinoma
Gregory L. Beatty
ONCOIMMUNOLOGY (2014)
Expression profiling of TCR-engineered T cells demonstrates overexpression of multiple inhibitory receptors in persisting lymphocytes
Daniel Abate-Daga et al.
BLOOD (2013)
Immune targeting of fibroblast activation protein triggers recognition of multipotent bone marrow stromal cells and cachexia
Eric Tran et al.
JOURNAL OF EXPERIMENTAL MEDICINE (2013)
Chimeric antigen receptor containing ICOS signaling domain mediates specific and efficient antitumor effect of T cells against EGFRvIII expressing glioma
Chan-Juan Shen et al.
JOURNAL OF HEMATOLOGY & ONCOLOGY (2013)
Increased Survival in Pancreatic Cancer with nab-Paclitaxel plus Gemcitabine
Daniel D. Von Hoff et al.
NEW ENGLAND JOURNAL OF MEDICINE (2013)
B-cell depletion and remissions of malignancy along with cytokine-associated toxicity in a clinical trial of anti-CD19 chimeric-antigen-receptor-transduced T cells
James N. Kochenderfer et al.
BLOOD (2012)
Redirecting Gene-Modified T Cells toward Various Cancer Types Using Tagged Antibodies
Koji Tamada et al.
CLINICAL CANCER RESEARCH (2012)
Redirected T Cells That Target Pancreatic Adenocarcinoma Antigens Eliminate Tumors and Metastases in Mice
Amit Maliar et al.
GASTROENTEROLOGY (2012)
T Cells That Target Carcinoembryonic Antigen Eradicate Orthotopic Pancreatic Carcinomas Without Inducing Autoimmune Colitis in Mice
Markus Chmielewski et al.
GASTROENTEROLOGY (2012)
Redirected Antitumor Activity of Primary Human Lymphocytes Transduced With a Fully Human Anti-mesothelin Chimeric Receptor
Evripidis Lanitis et al.
MOLECULAR THERAPY (2012)
Expression of a Functional CCR2 Receptor Enhances Tumor Localization and Tumor Eradication by Retargeted Human T cells Expressing a Mesothelin-Specific Chimeric Antibody Receptor
Edmund K. Moon et al.
CLINICAL CANCER RESEARCH (2011)
FOLFIRINOX versus Gemcitabine for Metastatic Pancreatic Cancer
Thierry Conroy et al.
NEW ENGLAND JOURNAL OF MEDICINE (2011)
Chimeric Antigen Receptor-Modified T Cells in Chronic Lymphoid Leukemia
David L. Porter et al.
NEW ENGLAND JOURNAL OF MEDICINE (2011)
Engineered T cells for pancreatic cancer treatment
Usha L. Katari et al.
HPB (2011)
Eradication of B-lineage cells and regression of lymphoma in a patient treated with autologous T cells genetically engineered to recognize CD19
James N. Kochenderfer et al.
BLOOD (2010)
Mesothelial proteins are expressed in the human cornea
Katerina Jirsova et al.
EXPERIMENTAL EYE RESEARCH (2010)
Case Report of a Serious Adverse Event Following the Administration of T Cells Transduced With a Chimeric Antigen Receptor Recognizing ERBB2
Richard A. Morgan et al.
MOLECULAR THERAPY (2010)
HER2 overexpression correlates with survival after curative resection of pancreatic cancer
Masahiro Komoto et al.
CANCER SCIENCE (2009)
Control of large, established tumor xenografts with genetically retargeted human T cells containing CD28 and CD137 domains
Carmine Carpenito et al.
PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA (2009)
4-1BB is superior to CD28 costimulation for generating CD8+ cytotoxic lymphocytes for adoptive immunotherapy
Hua Zhang et al.
JOURNAL OF IMMUNOLOGY (2007)
Mesothelin-specific CD8+ T cell responses provide evidence of in vivo cross-priming by antigen-presenting cells in vaccinated pancreatic cancer patients
AM Thomas et al.
JOURNAL OF EXPERIMENTAL MEDICINE (2004)
MUC1 expression in primary and metastatic pancreatic cancer cells for in vitro treatment by 213Bi-C595 radioimmunoconjugate
CF Qu et al.
BRITISH JOURNAL OF CANCER (2004)
Expression of CD24 in adenocarcinomas of the pancreas correlates with higher tumor grades
J Jacob et al.
PANCREATOLOGY (2004)
Carcinoembryonic antigen as a target for therapeutic anticancer vaccines: A review
NL Berinstein
JOURNAL OF CLINICAL ONCOLOGY (2002)
Share Paper
